Regulatory authorities often fast-track vaccines that can potentially end pandemic threats to public health. However, developing a process-specific ELISA may require 1 - 2 years for antibody development and assay validation. Even then, there are examples of inadequate impurity detection and clearance in commercial vaccine products, causing patient safety issues. LC-MS assays are robust, quantitative, highly sensitive, and require only 6-8 weeks to be established and optimized for any biologic product. This can significantly accelerate the development, marketing approval, and commercial biomanufacturing of vaccine products while ensuring the highest levels of product quality and patient safety. The FDA and EMA have already approved release testing for vaccine products in Phase-III clinical trials based on MS-only HCP analysis data under GMP conditions provided by us.